Introduction
Antiphospholipid syndrome (APS) is an auto-Ab-mediated prothrombotic disorder characterized by recurrent venous and arterial thromboembolic events. It is defined by the Sapporo criteria as the presence of antiphospholipid Abs, either lupus anticoagulant (LA), anticardiolipin antibodies (ACAs) or anti-b 2 -glycoprotein Abs (b 2 GP1) with occurrence of either thromboembolic events or pregnancy morbidity. 1 Administration of anticoagulant and antiplatelet agents is the standard therapeutic intervention for patients who develop thromboembolic manifestation. Some patients show more serious complications with a very high auto-Ab titer and with failure of anticoagulant and antiplatelet agents to prevent thrombosis. These patients may require immunomodulation to control the disease.
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Case report A 34-year-old male was diagnosed as having primary APS fulfilling the Sapporo criteria. He first presented at the age of 25 years with deep venous thrombosis. He was treated with standard anticoagulation therapy and maintained at an INR of 2-3. Over 3 years, he had five additional episodes of deep venous thrombosis/pulmonary embolism, with peripheral ischemia and suspicion of acute myocardial infarction. He was referred to our institution for further management and for cardiac catheterization. However, because of extensive thrombosis, cardiac catheterization could not be performed, and he was continued on warfarin at the same dose in addition to aspirin 325 mg. Initial workup showed the presence of strong LA with an LA ratio of 4.2 (positive 41.35), ACA IgG was 633 IgG phospholipid (GPL)/mL, b 2 GP1 IgG was 928 GPL/mL and both ANA and dsDNA were negative. He was positive for activated protein C resistant ratio. All other thrombophilia tests, including molecular studies for factor V Leiden and prothrombin 20210 mutations were negative. Complete blood count, liver function and renal functions were all within normal ranges. The patient was switched to low molecular weight heparin and monitored with the intention of giving anti-Xa of 0.5-1.0 U/mL because of the difficulty of maintaining him at a therapeutic INR.
During the follow-up, while he was taking 120 mg of enoxaparin (1 mg/kg b.i.d.), he presented with Budd-Chiari syndrome with a subtherapeutic anti-Xa (0.2 U/mL) and an ACA IgG titer 751 GPL/mL. This was followed by three more thrombotic attacks and a rise in ACA titer to 1456 GPL/mL, which placed him in a high-risk category and made him a candidate for immunomodulation. Before initiation of immunomodulation, and during routine workup, a CT scan of the chest showed small mediastinal and paraaortic lymph nodes. The results of further workup to exclude the presence of lymphoma, including a PET scan and a BM examination, were negative. He received two courses of rituximab (375 mg/m 2 ) with each course divided into four doses given weekly. On reevaluation after rituximab treatment, he showed a decrease in the titer for ACA IgG from 1456 to 186 GPL/mL and LA ratio from 4.2 to 2.3. However, after a few months he presented with bilateral adrenal infarcts and iliac vein thrombosis while receiving therapeutic low molecular weight heparin with an ACA IgG titer of 543 GPL/mL. He was switched to fondaparinux 10 mg/day with monthly plasmapheresis. After a few months, he presented with catastrophic antiphospholipid syndrome (CAPS; renal impairment, pneumonitis and a thrombotic thrombocytopenic purpura-like picture), with a b 2 GP1 IgG titer of 468 GPL/mL and was treated with unfractionated heparin in addition to high-dose methylprednisolone 1 g/day for 3 days, i.v. IgG 0.4 g/day for 5 days and VCR 2 mg i.v. once. He responded initially to plasma exchange, but due to failure to secure i.v. access for plasmapheresis (almost all central access points were thrombosed), he was offered high-dose chemotherapy and autologous SCT. He was mobilized with G-CSF 10 mg/kg and harvested when the WBC was 10.4 Â 10 9 per L. In May 2008, he was conditioned with CY 50 mg/kg/day i.v. (total dose 200 mg/kg) and ATG 30 mg/kg/day i.v. (total dose 90 mg/ kg), followed by infusion of CD34 with a total dose of (4.3 Â 10 6 per kg). After a stormy course post transplant complicated by infections (multidrug-resistant Klebsiella pneumonia treated with multiple courses of antibiotics and CMV antigenemia treated with ganciclovir) and two episodes of stroke, which resulted in hemiplegia and an epileptic attack, the patient was discharged on anticoagulation (enoxaparin and clopidogrel). At almost 2-year post transplant and during regular monthly followup, he had not developed any episodes of thrombosis and had recovery of the peripheral count and a virtually entire absence of antiphospholipid Abs. He was fully ambulatory with no evidence of residual effects of stroke except for being on controlled antiepileptic drugs. However, he continued taking a prophylactic dose of low molecular weight heparin until 2 months ago when he decided to stop the anticoagulant (Figure 1 ).
Discussion and review of literature
Treatment of APS can be challenging and may require use of various therapeutic modalities including immunomodulation. 2, 3 We report a patient with more than 15 venous and arterial thrombotic events uncontrolled by anticoagulant and anti-plt agents, with progression to CAPS. Immunomodulants including rituximab, steroids, i.v. Ig, VCR and plasmapheresis were used to control the disease. There was initial response to treatment with rituximab, but the patient presented later with CAPS. There are a few anecdotal reports about the effectiveness of rituximab in APS. 2 Other immunomodulant measures including plasmapheresis alone or in combination with i.v. Ig have been proposed as the treatment of choice in patients with CAPS. [4] [5] [6] The concept of using SCT for treatment of refractory autoimmune disorders was introduced to medical practice after early encouraging data in animal models. [7] [8] [9] In autoimmune conditions, disease arises from failure to inhibit polyclonal expansion and activation upon exposure to self-Ags that results from a failure of normal mechanisms to suppress proliferation in the presence of innocuous or self-Ags. 8, 9 The rational behind using SCT is based on ablation of clonal memory cells by cytotoxic drugs followed by introduction of stem cells for immune reconstitution, or an 'immune reset'. 9, 10 Because the first report of successful autologous SCT procedure for systemic lupus erythematosus (SLE) by Marmont et al., 11 many larger studies have shown the beneficial effect of both autologous and allogeneic SCT in SLE and other autoimmune disorders such as rheumatoid arthritis (RA) systemic sclerosis, inflammatory bowel disease and autoimmune thyroiditis. [12] [13] [14] [15] [16] Although most of these reports had few patients, the response rate was encouraging. Burt et al. showed a successful outcome in SLE patients after autologous SCT with 50% disease-free survival. 17, 18 The same concept has been applied to patients with RA. In mid-1980, Jacob et al. showed a prolonged remission in patients with severe RA who received allogeneic SCT for drug-induced BM aplasia. 19 This observation was confirmed later in a few small reports in patients with RA treated with SCT who achieved prolonged remissions. 20, 21 Currently, data are available from more than 70 patients who have undergone autologous SCT for RA. However, while most centers reported an initial response to SCT in patients with autoimmune disorders, recurrence of disease is a common theme. 9, 12 The successful results of SCT for some autoimmune disorders have encouraged physicians to extend the use for other autoimmune disorders including APS. Early animal models showed the effectiveness of SCT in APS. 3 This observation was not translated to clinical practice until the end of the 1990s when Olalla et al. 22 reported the first case of disappearance of LA Abs in a patient without SLE treated with allogeneic SCT for chronic myeloid leukemia. Most reported studies described SCT for APS secondary to SLE. 23 Figure 1 The level of antiphospholipid Abs before and after treatment.
Brief Report secondary APS in a large cohort of SLE patients who received autologous SCT. They reported disappearance of LA in 75% of the patients and normalization of ACA in up to 82% of patients. 25 Anticoagulation was discontinued in 82% of the patients within 4 months after SCT. Burt et al. 17 reported the same result for anticoagulation in a subgroup analysis of the same SLE cohort patients. A different conditioning region for SCT was used while a nonmyeloablative dose of CY and ATG were commonly used, 17, 25 whereas in other studies a conditioning regimen included TBI or BEAM protocol. 12 In our patient, the levels of all antiphospholipid Abs normalized post transplant and continued for about 2 years in the follow-up period; however, because of the severity of the disease, we elected to continue anticoagulation. The patient then decided himself to stop the anticoagulation and has had no thrombotic attacks in a 2-month follow-up period.
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